Genetron Health's early cancer screening segment focuses on the development and commercialization of innovative diagnostic tests for the early detection of cancer, particularly hepatocellular carcinoma (HCC). This segment leverages proprietary assays like HCCscreen, which utilizes advanced molecular biology techniques to identify biomarkers associated with early-stage cancer. Research and development efforts are directed towards improving the sensitivity and specificity of these tests, as well as expanding their application to other cancer types. The goal is to enable earlier diagnosis and intervention, leading to improved patient outcomes and reduced healthcare costs. This segment addresses a critical unmet need in cancer care by providing accessible and reliable screening solutions for high-risk populations.

The Diagnostics and Monitoring segment at Genetron Health is dedicated to providing comprehensive molecular profiling services for cancer patients. This includes laboratory-developed tests (LDTs) and in-vitro diagnostic (IVD) products designed to identify actionable mutations and guide treatment decisions. Key technologies employed in this segment include next-generation sequencing (NGS), digital PCR, and biochip analysis. The segment's offerings encompass a range of assays for various cancer types, including lung cancer, glioma, and other solid tumors. By providing clinicians with detailed molecular information about each patient's cancer, this segment enables personalized treatment strategies and improves patient outcomes. Ongoing research and development efforts focus on expanding the test menu, enhancing analytical capabilities, and incorporating new biomarkers to further refine diagnostic accuracy and predictive power.

Genetron Health's Biopharma Services segment offers comprehensive genomics research and clinical development services to biopharmaceutical companies, hospitals, and research institutions worldwide. This segment leverages the company's expertise in molecular biology, data science, and clinical research to support drug discovery, clinical trial design, and biomarker development. Services include genomic sequencing, data analysis, bioinformatics, and clinical trial support. By partnering with leading biopharmaceutical companies, Genetron Health contributes to the development of innovative cancer therapies and personalized treatment strategies. This segment plays a crucial role in advancing precision oncology by facilitating the translation of genomic discoveries into clinical applications and improving patient outcomes.